(Q24187385)

secondary hyperparathyroidism

inferred from title

1 reference

1

Angela E Ballinger

0 references

Suetonia Palmer

2

0 references

Jonathan Craig

4

object named as

Jonathan C Craig

0 references

Giovanni Strippoli

5

object named as

Giovanni FM Strippoli

0 references

Ionut Nistor

Cochrane Database of Systematic Reviews

3

object named as

Ionut Nistor

0 references

language of work or name

English

0 references

publication date

9 December 2014

0 references

published in

0 references

issue

12

0 references

page(s)

CD006254

0 references

cites work

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Clinical study of cinacalcet in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Hyperphosphataemia in renal failure: causes, consequences and current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Bias in location and selection of studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Parathyroidectomy rates among United States dialysis patients: 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Publication bias: the case for an international registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Osteoporosis and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Calcimimetic agents: review and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Meta-analysis of biochemical and patient-level effects of calcimimetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Are surrogate markers adequate to assess cardiovascular disease drugs?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254.PUB2

7 January 2021

10.1002/14651858.CD006254.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

886470

886470

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference